Ibrunib

Clinical Trials

Extensive clinical trials (e.g., RESONATE, RESONATE-2, HELIOS, PCYC-1104, PCYC-1115) have demonstrated Ibrutinib's efficacy and safety across multiple indications, leading to its global approvals.

Lab Monitoring

• Complete Blood Count (CBC) with differential (monthly or more frequently if clinically indicated).
• Liver function tests (LFTs) periodically.
• Renal function tests periodically.

Doctor Notes

• Counsel patients on potential bleeding events and signs of infection.
• Monitor CBC, LFTs, and renal function regularly.
• Review concomitant medications for potential drug interactions, especially CYP3A inhibitors/inducers.
• Advise patients to report any new onset atrial fibrillation or symptoms of cardiac events.

Patient Guidelines

• Take Ibrutinib exactly as prescribed by your doctor.
• Do not open, crush, or chew the capsules.
• Report any signs of bleeding, infection, or cardiac events immediately.
• Avoid grapefruit and Seville oranges.
• Inform your doctor about all other medications, supplements, and herbal products you are taking.

Missed Dose Advice

If a dose is missed, take it as soon as you remember on the same day. Do not take two doses to make up for a missed dose. Return to your regular dosing schedule the next day.

Driving Precautions

Ibrutinib may cause fatigue, dizziness, or blurred vision. Patients should exercise caution when driving or operating machinery until they know how the medication affects them.

Lifestyle Advice

• Maintain good hydration.
• Practice good hygiene to reduce infection risk.
• Avoid activities that may increase bleeding risk.
• Monitor blood pressure regularly if advised.